Table 1.
Baseline demographic, cardiovascular and disease characteristics in early diffuse systemic sclerosis (SSc) patients compared to controls
| Early diffuse SSc n=15 |
Healthy Controls n=15 |
p-value | |
|---|---|---|---|
| Demographic | |||
| Mean age | 49.5 ± 14.3 | 47.5 ± 13.7 | 0.80 |
| Female (%) | 62% | 62% | -- |
| Caucasian (%) | 93% | 93% | -- |
| Cardiovascular Risk Factors | |||
| Mean body mass index | 27.4 ± 6.2 | 27.5 ± 5.6 | 0.71 |
| Hypertension | 13% | 27% | 0.65 |
| Diabetes Mellitus | 0% | 0% | 1.00 |
| Hyperlipidemia | 47% | 53% | 0.99 |
| Tobacco use | 13% | 0% | 0.48 |
| Family history of cardiovascular disease | 20% | 27% | 0.92 |
| SSc disease characteristics | |||
| Mean disease duration ± SD | 1.3 ± 0.5 years | ||
| Mean modified Rodnan skin score ± SD | 20.2 ± 8.7 | ||
| Active tendon friction rubs | 47% | ||
| Raynaud phenomena | 86% | ||
| Digital pitting scars | 36% | ||
| Digital ulcers | 29% | ||
| Telangiectasias | 20% | ||
| Interstitial lung disease | 43% | ||
| Gastrointestinal manifestations | 43% | ||
| Cardiac manifestations | 0% | ||
| Scleroderma renal crisis | 0% | ||
| Medication use | |||
| Mycophenolate mofetil | 40% | - | |
| D-penicillamine | 40% | - | |
| Methotrexate | 7% | - | |
| Cyclophosphamide | 7% | - | |
| Calcium channel blockers | 40% | 0% | 0.02 |
| Angiotensin receptor blockers | 0% | 0% | 1.0 |
| Ace-Inhibitors | 13% | 7% | 0.99 |
| Statin use | 27% | 20% | 0.99 |